---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-060160"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2026-05-21T21:20:15+00:00"
generated_at: "2026-05-21T21:27:38.950659+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech gets $412.5K additional convertible loan at $0.08/share; increases consideration shares to 12.15M

## Summary
- Additional loan of $412,500 (net $375,000) from AlpineBrook Capital; convertible at $0.08/share and warrant exercisable at $0.08/share.
- Consideration shares increased to 12,147,280, to be delivered in five installments over 25 months.
- Voting agreement with major shareholders to support increase in authorized shares for conversion and warrant exercise.
- Loan matures on Maturity Date under existing Loan Agreement; interest at Applicable Rate, 360-day year.

## SEC filing metadata
- accession: 0001213900-26-060160
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2026-05-21T21:20:15+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390026060160/0001213900-26-060160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390026060160/ea0291582-8k_nkgen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-060160
- JSON: https://secwatch.observer/filing/0001213900-26-060160.json
- Plain text: https://secwatch.observer/filing/0001213900-26-060160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.